Compare STRL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRL | GH |
|---|---|---|
| Founded | 1955 | 2011 |
| Country | United States | United States |
| Employees | 1740 | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 13.3B |
| IPO Year | 1996 | 2018 |
| Metric | STRL | GH |
|---|---|---|
| Price | $472.64 | $82.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $475.50 | $119.79 |
| AVG Volume (30 Days) | 420.7K | ★ 2.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.42 | 6.74 |
| EPS | ★ 9.38 | N/A |
| Revenue | $957,958,000.00 | ★ $982,021,000.00 |
| Revenue This Year | $26.70 | $33.30 |
| Revenue Next Year | $11.63 | $28.27 |
| P/E Ratio | $50.48 | ★ N/A |
| Revenue Growth | ★ 38.81 | 32.88 |
| 52 Week Low | $151.50 | $36.36 |
| 52 Week High | $512.36 | $120.74 |
| Indicator | STRL | GH |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 41.17 |
| Support Level | $307.44 | $82.33 |
| Resistance Level | N/A | $92.73 |
| Average True Range (ATR) | 20.91 | 5.10 |
| MACD | 1.46 | -0.20 |
| Stochastic Oscillator | 49.03 | 40.14 |
Sterling Infrastructure Inc operates through subsidiaries within three segments: E-Infrastructure, Transportation, and Building Solutions in the United States, mainly across the Southern, Northeastern, Mid-Atlantic, and Rocky Mountain regions and the Pacific Islands. E-Infrastructure Solutions generates maximum revenue and provides site development and mission-critical electrical services for data centers, manufacturing, distribution centers, warehousing, and power generation. Transportation Solutions includes infrastructure and rehabilitation projects for highways, airports, ports, rail, and storm drainage systems. Building Solutions includes residential and commercial concrete foundations, parking structures, plumbing services, and surveys for new single-family residential builds.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.